March 2006 Br J Cardiol 2006;13:86-8
Philip A Poole-Wilson, Fernando A Botoni
Treatment of chronic heart failure (CHF), an important cause of global morbidity and mortality, has evolved in the last three decades.1-3 Activation of neurohormonal systems plays a key role in the pathophysiology and progression of the disease. Therapeutic strategies directed towards their inhibition have reduced morbidity and mortality.3 The major mechanism seems to be related to the inhibition or reversal of remodelling.4 Angiotensin-converting enzyme (ACE) inhibitors are known to reduce symptoms and improve prognosis. The benefit of beta blockers in patients with heart failure has been amply demonstrated by comparing outcomes in patients prescribed a beta blocker or a placebo in patients on optimal treatment with diuretics and ACE inhibitors.
January 2006 Br J Cardiol 2006;13:5-6
Gervasio A Lamas, Steven J Hussein
According to World Health Organization estimates, 16.7 million people die of cardiovascular diseases each year. By the year 2010, it is estimated that cardiovascular disease will become the leading cause of death in developing countries and by 2020 it will contribute to nearly 25 million deaths worldwide. Although therapies including drugs, lifestyle modification and revascularisation procedures have been demonstrated in clinical trials to be beneficial, they are under-utilised. Paradoxically, in spite of the under-use of evidence-based therapies, patients actively seek complemen- tary and alternative medicine (CAM) treatments. While many alternative therapies involve oral vitamin and mineral supple- ments that are unlikely to cause harm, chelation therapy is one of the most aggressive and intensive CAM modalities.
January 2006 Br J Cardiol 2006;13:9-12
Khalid Barakat, Graham A Hitman
Our understanding of the pathophysiology of acute coronary syndromes and, in particular, the interplay of a number of complex parallel processes, continues to develop.1 These processes include inflammation, thrombosis and matrix turnover with potential gene and environmental influences. Vitamin D, known primarily as a hormone of bone metabolism, can affect the transcription of a number of genes which play a pivotal role in both the development of acute coronary syndromes and the pathogenesis of coronary artery disease (CAD). The purpose of this review is to examine the mechanisms by which vitamin D and the vitamin D receptor (VDR) might influence the development of acute coronary syndromes.
November 2005 Br J Cardiol 2005;12:439-40
We continue our series where Consultant Interventionist Dr Michael Norell takes a sideways look at life in the
cath lab ….. and beyond. In this column, he looks at the unreal and riveting world of TV medicine.
November 2005 Volume 12, Issue 6
Submissions are in and now the real lobbying can begin.
Scarcely a year after the implementation of the Quality
and Outcomes Framework (QOF) of the new General
Medical Services (GMS) contract,1 the first review is already
well underway and due to come into effect on 1st April 2006.
November 2005 Br J Cardiol 2005;12:409-10
Alan G Begg
As an organisation we are delighted that, as from this
issue, The British Journal of Cardiology will become
the official journal of the Scottish Heart and Arterial
Risk Prevention group (SHARP). SHARP, a registered charity
launched in Scotland in 1988, now attracts members from
across the UK bringing together a wide range of healthcare
professionals interested in the prevention and management
of cardiovascular disease (CVD).
September 2005 Br J Cardiol 2005;12:336-8
The Anglo-Scandinavian Cardiac Outcomes Trial
(ASCOT) reported the final results of its blood pressure
lowering arm at the European Society of Cardiology
(ESC) Annual meeting amidst much publicity.
September 2005 Br J Cardiol 2005;12:333-5
Emma J Birks
Heart failure affects over 750,000 people in the UK and
65,000 new cases are diagnosed every year. It carries a
poor prognosis with a population-based study finding
a 40% one-year mortality in all new diagnosed cases1 with
those in New York Heart Association (NYHA) class IV having a
60% one-year mortality.
July 2005 Br J Cardiol (Acute Interv) Cardiol 2005;12:AIC 42–AIC 44
Adrian P Banning
Drug-eluting stents (DES) have been available commercially in the UK for over three years. The National Institute for Clinical Excellence (NICE) produced a technology appraisal in October 2003 and that initial review is about to be updated. Well, has this technology delivered on its promise? Have we embraced it too quickly or is 100% DES usage around the corner?
July 2005 Br J Cardiol 2005;12:255-6
David A Fitzmaurice
The association between mitral valve disease, atrial
fibrillation (AF) and the incidence of embolic stroke is well
known. The incidence of systemic embolism (including
embolic stroke) is seven times greater in patients with mitral
valve disease and AF.